Greenwich LifeSciences, Inc.

GLSI

Healthcare Biotechnology

EPS
+3.57%
Free cash flow
+13.1%

Quarter to June 2026, against a year earlier

15.17 0.52 +3.55%
Market cap
$222.7M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.3×
Dividend safety
n/a
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Current Ratio
0.00 0.12 0.00 27.41 70.62 51.23 23.74 1.28 1.06
Net Debt/EBITDA
0.00 0.05 0.00 15.41 5.92 1.68 0.75 0.23 0.32
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
16.86% 18.11% 59.69% (14.18%) (16.78%) (39.08%) (89.30%) (457.73%) (3,068.35%)
ROA
(2,320.80%) (3,114.65%) (5,067.01%) (12.98%) (16.35%) (38.46%) (86.87%) (314.09%) (376.92%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
282.29% 262.58% 249.97% (6.75%) (17.04%) (59.26%) (132.81%) (1,920.19%) (5,480.80%)
Free Cash Flow per Share
(0.01) (0.01) (0.13) (0.12) (0.33) (0.48) (0.50) (0.56) (0.73)
Book value per Share
(0.73) (0.86) (0.60) 2.91 2.07 1.02 0.52 0.07 0.03
Free Cash Flow
(0.12) (0.11) (0.29) (1.15) (4.29) (6.20) (6.48) (7.27) (9.91)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026